Every 8-K that KORU Medical Systems, Inc. (KRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRMD filings page.
KORU Medical Systems, Inc. reports a governance change approved by its Board of Directors effective August 13, 2026. The company amended Section 3.05 of its Amended and Restated By-laws so that, consistent with the Delaware General Corporation Law, the authority to remove any director rests exclusively with shareholders through an affirmative vote of holders of a majority of the company’s outstanding shares.
The Board states it has never voted to remove a director and has no intention or agreement to do so. The amendment is filed as an exhibit to this report.
KORU Medical Systems, Inc. reported second quarter 2026 net revenues of $12.0 million, up 18.2% from $10.2 million a year earlier, driven by 12.4% domestic core growth and 59.1% international core growth. Pharma services and clinical trials revenue declined 35.0% to $0.6 million.
Gross profit rose to $7.8 million with gross margin improving to 65.1%, while operating expenses increased 6.3% to $7.2 million. Net income was $0.25 million, or $0.01 per diluted share, compared with a net loss of $0.21 million. Adjusted EBITDA grew to $0.9 million, or $0.02 per adjusted diluted share.
Cash and cash equivalents were $8.3 million as of June 30, 2026, after $0.5 million of cash usage in the quarter. The company acquired a connected monitoring technology asset and entered a multi-year supply agreement. Full-year 2026 guidance now calls for net revenues of $47.5–$48.5 million, gross margin of 62–64%, positive adjusted EBITDA, and year-end cash above $7.5 million. KORU also withdrew its Phesgo® 510(k) and refocused its U.S. oncology strategy on higher-volume molecules.
KORU Medical Systems, Inc. entered into Amendment No. 1 to its Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, LLC. Command manufactures and supplies KORU’s subassemblies, needle sets and tubing products under this agreement.
The amendment extends the initial term so the agreement now runs through December 31, 2031, with automatic one-year renewals unless either party gives at least 180 days notice not to renew. It also revises pricing and payment terms, including product pricing, annual price adjustments and pass-through cost savings.
The amendment adds requirements for Command to obtain and qualify a second manufacturing site by December 31, 2027, and gives KORU a new right to terminate if Command misses this requirement and does not cure within 30 days. Command becomes the exclusive manufacturer of a limited set of products, wind-up period provisions are broadened, intellectual property ownership and licenses are clarified, assignment rights are made mutual, and a prior non-competition provision is removed. Other termination rights, including for uncured material breach within 45 days, bankruptcy or insolvency, and force majeure events lasting at least 30 days, remain in place.
KORU Medical Systems, Inc. reported the results of its 2026 annual shareholder meeting. Shareholders elected all seven director nominees and cast votes on 36,678,784 shares. They approved an amendment to the 2024 Omnibus Equity Incentive Plan to increase available shares and gave advisory approval to executive compensation.
Shareholders also advised holding future say-on-pay votes every one year and ratified Cherry Bekaert LLP as independent registered public accountants for the 2026 fiscal year. Overall, all management proposals received strong support.
KORU Medical Systems reported strong first quarter 2026 growth while remaining modestly loss-making. Net revenues rose 22.1% to $11.8 million, driven by 11.7% domestic core growth to $7.7 million, 35.2% international core growth to $3.3 million, and 166.0% growth in pharma services and clinical trials to $0.7 million.
Gross profit increased to $7.2 million, though gross margin slipped to 61.5% from 62.8% due to higher production costs and tariff-related charges. Net loss improved to $0.8 million, or $0.02 per diluted share, from $1.2 million, or $0.03 per diluted share, with adjusted EBITDA near breakeven at negative $0.01 million.
Cash and cash equivalents were $8.8 million as of March 31, 2026, with minimal cash usage of about $0.1 million in the quarter. The company reiterated full-year 2026 guidance for net revenues of $47.5–$50.0 million, gross margin of 61–63%, and positive adjusted EBITDA and positive cash flow.
KORU Medical Systems, Inc. amended its loan and security agreement with HSBC Ventures USA Inc. covering a $5,000,000 revolving credit facility and a $5,000,000 term loan. The company has not drawn on this credit facility and is not required to do so.
The amendment extends the revolver maturity from December 31, 2026 to March 30, 2028 and the term loan maturity from December 1, 2028 to December 1, 2029. It also extends the term loan interest-only period to June 30, 2027, with a possible extension to December 31, 2027 if certain EBITDA milestones are met, lowers the interest rate floor to 5.50% from 6.50%, removes the adjusted quick ratio covenant, and adds a remaining months liquidity covenant of at least twelve months once the revolver is drawn.
KORU Medical Systems announced a planned leadership transition. President and Chief Executive Officer Linda Tharby will retire as CEO effective June 30, 2026, remaining a non‑executive advisory employee and Board member through December 31, 2026. Adam Kalbermatten will become President on March 15, 2026 and succeed her as CEO on July 1, 2026.
Tharby’s transition agreement provides continued salary through the transition date, prorated 2025–2026 bonuses under the annual incentive plan, partial continued vesting of certain RSUs, stock options and PSUs, and company‑paid COBRA premiums for 12 months beginning January 1, 2027, in exchange for ongoing advisory duties, restrictive covenants and sale restrictions on company equity during the advisory period.
Kalbermatten’s amended employment agreement sets annual base salary of $450,000 through June 30, 2026 and $525,000 starting July 1, 2026, with a prorated 2026 bonus paid 70% in cash and 30% in fully vested RSUs. He is slated to receive long‑term incentive awards with target grant values of $550,000 for 2025 and $1,250,000 for 2026, plus a one‑time CEO promotion PSU award of $1,250,000 effective July 1, 2026, all subject to performance and Compensation Committee approval. His agreement also outlines severance, equity vesting and change‑of‑control protections.
KORU Medical Systems reported strong growth for the fourth quarter and full year 2025 and issued an optimistic 2026 outlook. Fourth quarter 2025 net revenues rose 23% to $10.9 million, driven by 18% growth in domestic core and 71% growth in international core markets.
For 2025, net revenues increased 22% to $41.1 million, with gross profit up 20% to $25.6 million and gross margin at 62.3%. The company’s net loss narrowed to $2.6 million from $6.1 million, while adjusted EBITDA turned positive at $0.6 million versus a loss in 2024. Cash and cash equivalents were $8.9 million at year-end.
Management highlighted regulatory and pipeline milestones, including 510(k) clearance for use with UCB’s RYSTIGGO and EU MDR certification for the Freedom60 system with prefilled syringe compatibility, along with new pharma collaborations. For 2026, KORU Medical guided to net revenues of $47.5–$50.0 million (15–22% growth), gross margin of 61–63%, and positive adjusted EBITDA and cash flow.
KORU Medical Systems, Inc. amended and restated its By-laws effective February 5, 2026. The Board updated the By-laws to address Securities and Exchange Commission rules on universal proxy cards and to reflect a periodic review of governance provisions.
The revisions enhance procedural mechanics and disclosure requirements for stockholders who nominate directors or submit proposals at annual and special meetings. Changes include additional disclosures, representations and acknowledgments from nominating or proposing stockholders and their nominees, and revised advance notice deadlines for director nominations when the number of directors increases under certain circumstances.
KORU Medical Systems, Inc. reported that it has released a press release with certain preliminary financial results for the fiscal quarter and full year ended December 31, 2025. These figures are based on the company’s current estimates and may change after completion of its normal closing and review procedures. The details of the preliminary results are provided in the press release included as Exhibit 99.1. The company specifies that this information is being furnished rather than filed under securities laws, which affects how it is incorporated into other regulatory documents.
KORU Medical Systems, Inc. entered into an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. on November 19, 2025. Effective as of January 1, 2024, the agreement replaces a prior manufacturing and supply agreement dated November 11, 2020.
Under the agreement, Command will manufacture and supply KORU’s subassemblies, needle sets and tubing products according to KORU’s specifications and purchase orders. The agreement runs through December 31, 2026 and automatically renews for one-year terms unless either party elects not to renew under its terms.
Either party may terminate the agreement for an uncured material breach within 45 days, upon the other party’s bankruptcy or insolvency, or as otherwise provided. The agreement also sets out terms for pricing and payment, rebates, purchase commitments based on KORU’s forecasts, and includes customary provisions covering delivery, inspection, warranties, quality management, business continuity, handling and transport, intellectual property, confidentiality and indemnification.
KORU Medical Systems (KRMD) reported Q3 2025 results and updated its full‑year 2025 financial guidance via a press release furnished as Exhibit 99.1. The quarter covered the period ended September 30, 2025, and a conference call was scheduled for November 12, 2025 at 4:30 p.m. Eastern Time.
The company highlighted use of non‑GAAP measures, including adjusted EBITDA and adjusted diluted EPS, with definitions provided and reconciliations to GAAP included in the press release. Management views these metrics as helpful for comparing ongoing operations. The information under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities.